Dinotefuran + Pyriproxyfen

Verify with FDA CVM →

242 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
242
Total Reports
8
Deaths Reported
330.0%
Death Rate

Active Ingredients

DinotefuranDinotefuran + PyriproxyfenPyriproxyfen

Administration Routes

TopicalUnknownOral

Species Affected

Dog 221
Cat 20
Unknown 1

Most Affected Breeds

Retriever - Labrador 28
Domestic Shorthair 13
Pit Bull 11
Retriever - Golden 11
Boxer (German Boxer) 10
Collie - Border 9
Chihuahua 8
Terrier (unspecified) 8
Crossbred Canine/dog 8
Terrier - Yorkshire 7

Most Reported Reactions

Emesis 59
Vomiting 46
Lethargy (see also Central nervous system depression in 'Neurological') 41
Diarrhoea 18
Lack of efficacy (ectoparasite) - flea 14
Emesis (multiple) 13
Lack of efficacy - NOS 12
Other abnormal test result NOS 10
Behavioural disorder NOS 10
Weight loss 9
Seizure NOS 8
INEFFECTIVE, HOOKS 8

Outcome Breakdown

Recovered/Normal
135 (56.0%)
Outcome Unknown
75 (31.1%)
Ongoing
12 (5.0%)
Recovered with Sequela
11 (4.6%)
Euthanized
6 (2.5%)
Died
2 (0.8%)

Data Summary

Metric Value
Total adverse event reports 242
Reports involving death 8
Case-fatality rate (reported events) 330.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dinotefuran + Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 242 adverse event reports referencing Dinotefuran + Pyriproxyfen, including 8 reports in which the animal died — a 330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Dinotefuran, Dinotefuran + Pyriproxyfen, Pyriproxyfen. Reported administration routes include Topical, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dinotefuran + Pyriproxyfen reports are Dog (221 reports), Cat (20 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (28), Domestic Shorthair (13), Pit Bull (11) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dinotefuran + Pyriproxyfen are Emesis (59), Vomiting (46), Lethargy (see also Central nervous system depression in 'Neurological') (41), Diarrhoea (18). Of the 241 reports with a coded outcome, Recovered/Normal is the leading category at 56.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dinotefuran + Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial